March 04, 2015
1 min read
Save
This article is more than 5 years old. Information may no longer be current.
Valeant reports growth in fourth quarter, fiscal year 2014 revenues
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Valeant Pharmaceuticals totaled $8.3 billion in revenue in the fiscal year 2014, a 43% increase from 2013, according to a press release.
In the fourth quarter 2014, total revenue was $2.3 billion, a 10% increase from the fourth quarter 2013.
Ophthalmology revenues increased in all three of its segments in the fiscal year 2014. Ophthalmology Rx revenue totaled $465.4 million, a 108% increase from the previous year; contact lenses increased 174% to $170.4 million; and ophthalmology surgical totaled $215.1 million, a 138% increase.In the fourth quarter 2014, ophthalmology Rx revenue increased 8% to $131.8 million and contact lenses totaled $42.6 million for a 13% rise from the fourth quarter 2013. Ophthalmology surgical revenue decreased 5% to $56.6 million.
Bausch + Lomb’s organic growth was 8% in the fourth quarter and 11% in the fiscal year 2014.
GAAP earnings per share and cash earnings per share increased 34% to $2.67 and $8.34 in 2014.